Cargando…
Survey of Activated FLT3 Signaling in Leukemia
Activating mutations of FMS-like tyrosine kinase-3 (FLT3) are found in approximately 30% of patients with acute myeloid leukemia (AML). FLT3 is therefore an attractive drug target. However, the molecular mechanisms by which FLT3 mutations lead to cell transformation in AML remain unclear. To develop...
Autores principales: | Gu, Ting-lei, Nardone, Julie, Wang, Yi, Loriaux, Marc, Villén, Judit, Beausoleil, Sean, Tucker, Meghan, Kornhauser, Jon, Ren, Jianmin, MacNeill, Joan, Gygi, Steven P., Druker, Brian J., Heinrich, Michael C., Rush, John, Polakiewicz, Roberto D. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3084268/ https://www.ncbi.nlm.nih.gov/pubmed/21552520 http://dx.doi.org/10.1371/journal.pone.0019169 |
Ejemplares similares
-
Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients
por: Rosenberg, Mara W., et al.
Publicado: (2020) -
In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia
por: Glover, Jason M, et al.
Publicado: (2012) -
Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia
por: Rice, William G., et al.
Publicado: (2022) -
A BCR-ABL Mutant Lacking Direct Binding Sites for the GRB2, CBL and CRKL Adapter Proteins Fails to Induce Leukemia in Mice
por: Johnson, Kara J., et al.
Publicado: (2009) -
Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3
por: Nagai, Kozo, et al.
Publicado: (2018)